PD-L1 and survival in solid tumors: A meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Wu, Pin ^a,b   Wu, Dang ^b   Li, Lijun ^c   Chai, Ying ^a   Huang, Jian ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Hangzhou Xixi Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT MESOTHELIOMA; MELANOMA; OROPHARYNX CARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH CANCER; SURVIVAL TIME; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR ESCAPE; UTERINE CERVIX CANCER; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; MALE; META ANALYSIS; METABOLISM; MORTALITY; NEOPLASM; SURVIVAL RATE;

ANTIGENS, CD274; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; SURVIVAL RATE;

EID: 84938329177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131403     Document Type: Article

References (49)

1. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature reviews Immunology. 2013; 13(4):227-42. doi: 10.1038/nri3405 PMID: 23470321; PubMed Central PMCID: PMC3786574.
2. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current opinion in immunology. 2014; 27:89-97. doi: 10.1016/j.coi.2014.01.002 PMID: 24485523.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. doi: 10.1126/science.1203486 PMID: 21436444.
4. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. Current opinion in immunology. 2014; 27:16-25. doi: 10.1016/j.coi.2014.01.004 PMID: 24531241.
5. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010; 116(7): 1757-66. Epub 2010/02/10. doi: 10.1002/cncr.24899 PMID: 20143437.
6. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science translational medicine. 2012; 4(127):127ra37. Epub 2012/03/31. doi: 10.1126/scitranslmed.3003689 PMID: 22461641; PubMed Central PMCID: PMCPmc3568523.
7. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PloS one. 2013; 8(10):e76012. doi: 10.1371/journal.pone.0076012 PMID: 24124529; PubMed Central PMCID: PMC3790819.
8. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(15):5094-100. Epub 2004/08/07. doi: 10.1158/1078-0432.ccr-04-0428 PMID: 15297412.
9. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical oncology (Northwood, London, England). 2011; 28(3):682-8. Epub 2010/04/08. doi: 10.1007/s12032-010-9515-2 PMID: 20373055.
10. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. European journal of cancer (Oxford, England: 1990). 2014; 50(7):1361-9. Epub 2014/02/20. doi: 10.1016/j.ejca.2014.01.018 PMID: 24548766.
11. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory investigation; a journal of technical methods and pathology. 2014; 94(1):107-16. Epub 2013/11/13. doi: 10.1038/labinvest.2013.130 PMID: 24217091.
12. Chen XL, Yuan SX, Chen C, Mao YX, Xu G, Wang XY. [Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance]. Ai zheng = Aizheng = Chinese journal of cancer. 2009; 28(12):1328-32. Epub 2009/12/05. PMID: 19958630.
13. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(3):971-9. Epub 2009/02/04. doi: 10.1158/1078-0432.ccr-08-1608 PMID: 19188168.
14. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of experimental medicine. 2009; 206(6):1327-37. Epub 2009/05/20. doi: 10.1084/jem.20082173 PMID: 19451266; PubMed Central PMCID: PMCPmc2715058.
15. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer research. 2009; 69(20):8067-75. Epub 2009/10/15. doi: 10.1158/0008-5472.can-09-0901 PMID: 19826049.
16. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annual review of medicine. 2014; 65:185-202. doi: 10.1146/annurev-med-092012-112807 PMID: 24188664.
17. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. doi: 10.1038/nature13954 PMID: 25428505; PubMed Central PMCID: PMC4246418.
18. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. doi: 10.1038/nature13904 PMID: 25428503.
19. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. doi: 10.1038/nature14011 PMID: 25428504.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009; 6(7):e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070; PubMed Central PMCID: PMC2707010.
21. Deeks JJ HJ, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions 425 Chichester, UK: John Wiley & Sons. 2006.
22. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(15):4800-8. Epub 2008/08/05. doi: 10.1158/1078-0432.ccr-08-0731 PMID: 18676751.
23. Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J, et al. B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. International journal of clinical and experimental pathology. 2014; 7(9):6015-23. PMID: 25337246; PubMed Central PMCID: PMC4203217.
24. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012; 98(6):751-5. doi: 10.1700/1217.13499 PMID: 23389362.
25. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral oncology. 2011; 47(12):1148-53. Epub 2011/09/14. doi: 10.1016/j.oraloncology.2011.08.007 PMID: 21911310.
26. Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3(+) Tregs in gastric cancer and its clinical significance. International journal of clinical oncology. 2015; 20(2):273-81. doi: 10.1007/s10147-014-0701-7 PMID: 24804867.
27. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(9): 3360-5. Epub 2007/03/16. doi: 10.1073/pnas.0611533104 PMID: 17360651; PubMed Central PMCID: PMCPmc1805580.
28. Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Experimental and molecular pathology. 2014; 96(3):284-91. doi: 10.1016/j.yexmp.2014.03.005 PMID: 24657498.
29. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(20): 6341-7. Epub 2009/10/15. doi: 10.1158/1078-0432.ccr-09-1652 PMID: 19825956.
30. Liu Y, Carlsson R, Ambjorn M, Hasan M, Badn W, Darabi A, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013; 33(35):14231-45. Epub 2013/08/30. doi: 10.1523/jneurosci.5812-12.2013 PMID: 23986257.
31. Loos M, Langer R, Schuster T, Gertler R, Walch A, Rauser S, et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. The Annals of thoracic surgery. 2011; 91(4):1025-31. Epub 2011/03/29. doi: 10.1016/j.athoracsur.2010.12.041 PMID: 21440117.
32. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2014; 9(7):1036-40. doi: 10.1097/JTO.0000000000000177 PMID: 24926549; PubMed Central PMCID: PMC4058651.
33. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer immunology, immunotherapy: CII. 2007; 56(8):1173-82. Epub 2006/12/23. doi: 10.1007/s00262-006-0266-z PMID: 17186290.
34. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(8): 2947-53. Epub 2005/04/20. doi: 10.1158/1078-0432.ccr-04-1469 PMID: 15837746.
35. Ukpo OC, Thorstad WL, Lewis JS Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head and neck pathology. 2013; 7(2):113-21. Epub 2012/11/28. doi: 10.1007/s12105-012-0406-z PMID: 23179191; PubMed Central PMCID: PMCPmc3642256.
36. Wang Y, Zhuang Q, Zhou S, Hu Z, Lan R. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2009; 29(1):77-9. Epub 2009/02/19. doi: 10.1007/s11596-009-0116-2 PMID: 19224168.
37. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta histochemica. 2006; 108(1):19-24. Epub 2006/03/15. doi: 10.1016/j.acthis.2006.01.003 PMID: 16530813.
38. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Kufer R, et al. Association of T-cell coregulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014; 40(1):121-7. Epub 2013/10/22. doi: 10.1016/j.ejso.2013.08.023 PMID: 24140000.
39. Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Human immunology. 2014; 75(4): 348-53. doi: 10.1016/j.humimm.2014.01.006 PMID: 24468585.
40. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8(8): 793-800. Epub 2002/07/02. doi: 10.1038/nm730 PMID: 12091876.
41. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(19):12293-7. Epub 2002/09/10. doi: 10.1073/pnas.192461099 PMID: 12218188; PubMed Central PMCID: PMCPmc129438.
42. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature medicine. 2003; 9(5):562-7. Epub 2003/04/22. doi: 10.1038/nm863 PMID: 12704383.
43. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer research. 2003; 63(19):6501-5. Epub 2003/10/16. PMID: 14559843.
44. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer research. 2004; 64(3):1140-5. Epub 2004/02/12. PMID: 14871849.
45. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014; 515(7528):572-6. doi: 10.1038/nature14001 PMID: 25428506.
46. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. doi: 10.1038/nature13988 PMID: 25428507.
47. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366(26):2443-54. doi: 10.1056/NEJMoa1200690 PMID: 22658127; PubMed Central PMCID: PMC3544539.
48. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 366(26): 2455-65. doi: 10.1056/NEJMoa1200694 PMID: 22658128; PubMed Central PMCID: PMC3563263.
49. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine. 2015; 94(6):e515. doi: 10.1097/MD.0000000000000515 PMID: 25674748.